Shingrix Vaccine

Shingrix Vaccine is a recombinant, adjuvanted vaccine indicated for the prevention of herpes zoster (shingles) and post-herpetic neuralgia (PHN). It is formulated with a recombinant varicella zoster virus glycoprotein E (gE) antigen and an AS01B adjuvant system, designed to elicit a targeted immune response. This vaccine is recommended for adults aged 50 years and older, as well as adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy.

The vaccine is administered intramuscularly, typically into the deltoid region of the upper arm, as a 0.5 mL dose. For the vial and vial presentation, the lyophilized gE Antigen Component must be reconstituted with the accompanying Adjuvant Suspension Component prior to administration. A prefilled syringe presentation is also available, which does not require reconstitution.

Key Features : 

Antigen and target population: Contains recombinant varicella zoster virus glycoprotein E (gE) antigen with an AS01B adjuvant system, indicated for adults aged 50 years and older, and adults aged 18 years and older at increased risk of herpes zoster due to immunodeficiency or immunosuppression.
Cold-chain storage: Prior to reconstitution, both the antigen and adjuvant components must be stored refrigerated between 2°C and 8°C (36°F and 46°F), protected from light, and not frozen. After reconstitution, the vaccine should be administered immediately or stored refrigerated between 2°C and 8°C (36°F and 46°F) and used within 6 hours.
Route and schedule: Administered as a 0.5 mL intramuscular injection in a two-dose series. For immunocompetent adults, the second dose is given 2 to 6 months after the first, while for immunodeficient or immunosuppressed individuals, it is given 1 to 2 months after the first.
Regulatory: Approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).